Minoxidil for Androgenetic Alopecia

Verdict: Strong, proven treatment for pattern hair loss

Topical minoxidil genuinely works for androgenetic alopecia (male and female pattern hair loss), with consistent high-quality trial evidence and unanimous regulator and clinic backing placing it among the best-supported options. The catch is that it only maintains results while you keep using it, works best on the crown rather than the hairline, and not everyone responds.

S 🟢 S Strong Evidence Published

🔬Why this grade7-layer evidence engine

This earns the top Strong-Evidence (S) grade because the proof is unusually consistent and convergent. A meta-analysis of treatments for androgenetic alopecia (PMID 28396101) found both 5% and 2% topical minoxidil significantly outperformed placebo in men, and 2% in women, with P<0.00001 across all three comparisons. A 2026 systematic review (PMID 41695992) confirms topical minoxidil remains the only FDA-approved treatment for both sexes, and a 2025 meta-analysis (PMID 41127390) treats minoxidil monotherapy as the established active baseline that combination therapy is measured against.

Regulators and major clinics line up behind the trial data with no real dissent. The US FDA label approves it to regrow hair on the top (vertex) of the scalp; Mayo Clinic and Cleveland Clinic list it as the usual first-line option; Harvard Health states that 'only minoxidil and finasteride have been proven useful'; and the EADV specialty guideline gives it the strongest 'We recommend' rating at Level 1 evidence. This three-way agreement among trials, regulators, and clinics is what pushes it to S tier.

The grade reflects real benefit, not a cure. Regrown hair is lost within a few months of stopping, so it requires indefinite use; results are best at the crown rather than the frontal hairline; and a meaningful minority are non-responders. A separate dose-response meta-analysis of low-dose oral minoxidil (PMID 36161084) shows it also works (about +47 hairs/cm2 per mg/day) but is off-label, with cardiovascular and excess-hair side effects rising with dose.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.73
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
S · Published
Confidence
91%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.65
L2 PubMedPrimary literature
0.70
L5 Clinical bodiesAuthoritative stance
0.85
L11 AI re-checkIndependent read
0.95
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.73
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
  4. tier_strict_requirement_check — A 級條件達標
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis
PMID: 28396101 2017 統合分析
Finding: Topical minoxidil 5% and 2% both significantly superior to placebo in men, and 2% superior to placebo in women, for hair growth promotion (P<0.00001 for all three comparisons).
🟢 High quality Academic Effect size: P<0.00001 for 5% men, 2% men, and 2% women vs placebo
View on PubMed
Comparing minoxidil-finasteride mixed solution with minoxidil solution alone for male androgenetic alopecia: SR and MA of RCTs
PMID: 41127390 2025 統合分析 n = 396
Finding: Combination superior to minoxidil alone across all outcomes: hair density MD=9.22 (p=0.04), hair diameter MD=2.26 (p=0.005), photographic assessment MD=0.79 (p<0.00001), marked improvement OR=3.29 (p=0.015); confirms minoxidil monotherapy as active comparator baseline.
🟢 High quality Academic Effect size: MD 9.22 hairs/cm² (density); MD 2.26 μm (diameter); OR 3.29 (marked improvement)
View on PubMed
Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: SR with Meta-Regression
PMID: 36161084 2022 統合分析
Finding: Significant positive dose-response: each +1 mg/day LDOM associated with +47.1 hairs/cm² total density (p=0.007), +9.1 hairs/cm² terminal density (p=0.001), and +1.4 μm diameter (p=0.013); hypertrichosis risk +17.9%/mg (p=0.006), CV AE risk +4.8%/mg (p=0.004).
🟢 High quality Academic Effect size: +47.1 hairs/cm² per mg/day (total density)
View on PubMed
Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral and sublingual formulations
PMID: 41695992 2026 系統性回顧
Finding: Topical minoxidil remains only FDA-approved AGA treatment in both sexes; LDOM consistently effective for topical non-responders; sublingual route shows early non-inferior efficacy with potentially fewer CV effects. Hypertrichosis ~15% across formulations; CV AEs uncommon at low doses (fluid retention 1.3%, lightheadedness 1.7%, tachycardia 0.9%).
Academic
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
to regrow hair on the top of the scalp (vertex only, see pictures on side of carton) source↗
L4c UK NHS
Supportive
L4d TW TFDA / 衛福部
Supportive
醫師藥師藥劑生指示藥品 source↗
L5b Mayo Clinic
Supportive
Minoxidil (Rogaine). Over-the-counter (nonprescription) minoxidil comes in liquid, foam and shampoo forms. To be most effective, apply the product to the scalp skin once daily for women and twice daily for men. Many people prefer the foam applied when the hair is wet. Products with minoxidil help many people regrow their hair or slow the rate of hair loss or both. source↗
L5c Cleveland Clinic
Supportive
Over-the-counter (OTC) medications you apply to your scalp, such as minoxidil (Rogaine®), are usually the first course of treatment for male pattern baldness. Minoxidil may take two to four months of daily use before you notice any improvement in your hair loss. If you stop using either medication, your regrown hair will fall out. source↗
L5d Harvard Health
Supportive
only minoxidil and finasteride have been proven useful source↗
L5e Specialty Society (condition-mapped)
Supportive
Topical Minoxidil 2-5% solution 1 mL or half a cap of 5% foam twice daily is recommended to improve or to prevent progression of AGA in male patients above 18 years with mild to moderate AGA (Hamilton-Norwood IIv-V). [Strength of recommendation: ↑↑ 'We recommend'; Level of evidence 1] source↗

📰Related guidesEditorial coverage citing this evidence · 4 articles

PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-androgenetic-alopecia-INT-minoxidil-001 繁體中文版 →